Adverse events of mepolizumab in the treatment of nasal polyps: A FDA database evaluation
Mepolizumab treatment of CRSwNP is associated with fewer individual adverse reactions. Pulmonary reactions were, by far, the most common type of adverse reaction. Concurrent asthma treatment in CRSwNP-only-tx increases the number of reactions, and the seriousness of reactions and outcomes.
Authors
- Elias S. Saba (ORCID: https://orcid.org/0000-0001-6186-9912)
- Alejandra Salazar (ORCID: https://orcid.org/0000-0001-9505-1748)
- Kai Liu (ORCID: https://orcid.org/0009-0005-3640-6867)
- Jonathan Liang (ORCID: https://orcid.org/0009-0004-6510-9733)
- Brooke Stephanian
Institutions
- City College of New York (US)
- Kaiser Permanente Oakland Medical Center (US)
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- American Journal of Otolaryngology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1016/j.amjoto.2024.104517
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.65
Funders
- U.S. Food and Drug Administration